LRMR (larimartx.com) Future Price to Earnings

Larimar Therapeutics (LRMR) develops innovative therapies for central nervous system disorders. This chart on GURU.Markets shows a P/E ratio of 0.00, while the company minimizes costs by outsourcing drug production and testing. Growth potential is based on the massive unmet demand from patients with Friedreich's ataxia, which promises a rapid capture of the niche.

LRMR - Larimar Therapeutics Inc Projected Price to Earnings Ratio over the range 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for larimartx.com (LRMR)

- current price and projected stock value:

Stock Quotes Larimar Pharma|LRMR - Fair Value Consensus

- business market valuation indicators:

Market Value Larimar Therapeutics, Inc.|LRMR - Business Value

- balance sheet equity data:

Book Value per Share Larimar Therapeutics|LRMR - Total Stockholders' Equity|Market Cap to Net Assets Ratio larimartx.com|LRMR - Company Total Assets

- business debt structure and liquidity details:

- earnings and market ratios statistics:

LRMR - Annual Net Income|Future Profit Larimar Therapeutics|LRMR - Market Cap to Earnings|Future Price to Earnings Larimar Therapeutics|LRMR - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Larimar Pharma|LRMR - Operating profit EBITDA|Earnings per share for the last twelve months Larimar Therapeutics|LRMR - Earnings per share for the trailing year|Quarterly EPS earnings growth larimartx.com|LRMR - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Larimar Therapeutics

- sales and revenue data:

LRMR - Company Sales|Projected Sales Volume Larimar Therapeutics Inc|LRMR - P/S Multiple|Price-to-Projected Revenue Ratio Larimar Therapeutics|LRMR - Revenue Dynamics YoY (Last Twelve Months)

Analysis of all company metrics:LRMR Larimar Pharma

Signature product of Larimar Therapeutics

The metric is calculated as the ratio of the current market share price to the projected earnings per share. This indicator reflects market expectations regarding the business's future earnings. For Larimar Therapeutics (LRMR), whose developments in rare neurological diseases are independent of macroeconomic cycles, this metric becomes a key measure of investment risk. By analyzing the company's forward P/E ratio, an investor assesses the value of future clinical trial successes.

Competing companies